GlassScriptPhysician profile
Esteban Garces
NPI 1295176998
$1,803.77
in general payments reported to CMS, 2019-2025
25 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $252 · 2022: $427 · 2023: $378 · 2024: $344 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,114 · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.94 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $270.57 | 2021-2025 | Wegovy, Saxenda |
| Axsome Therapeutics, INC. | $267.46 | 2023-2025 | Sunosi |
| Abbvie INC. | $164.11 | 2021-2025 | |
| Ibsa Pharma INC. | $154.56 | 2021-2024 | Tirosint, Licart, Licart |
| Exact Sciences Corporation | $121.87 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $117.75 | 2021-2023 | Korlym |
| Acella Pharmaceuticals, LLC | $84.25 | 2022-2025 | NP Thyroid 60 |
| Mayne Pharma Commercial LLC | $72.28 | 2021-2025 | |
| Exeltis, USA INC. | $72.12 | 2021-2024 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $62.51 | 2022-2025 | |
| Acerus Pharmaceuticals Corporation | $58.33 | 2022 | |
| Avion Pharmaceuticals | $46.69 | 2022-2023 | Balcoltra |
| Therapeuticsmd, INC. | $44.95 | 2022 | |
| Idorsia Pharmaceuticals US INC | $38.80 | 2023 | Quviviq |
| Endo Pharmaceuticals INC. | $32.11 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $26.42 | 2021 | |
| Astellas Pharma US INC | $25.95 | 2025 | Veozah |
| Clarus Therapeutics INC. | $24.84 | 2021 | |
| Antares Pharma, INC. | $20.18 | 2025 | Xyosted |
| Millicent US INC | $19.02 | 2025 | Femring, Intrarosa |
| Sumitomo Pharma America, INC. | $17.62 | 2025 | Gemtesa |
| Tolmar, INC. | $17.32 | 2023 | |
| Lilly USA, LLC | $16.22 | 2024 | Zepbound |
| Azurity Pharmaceuticals, INC. | $15.80 | 2023 | Adthyza |
| Amgen INC. | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esteban Garces listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.